All News

The Center on Health Equity & Access provides news and expert insights on research, health policy, and the impact of social determinants on health.

Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.

Roberto Salgado, MD, anatomic pathologist for breast cancer translational research at Institut Jules Bordet, examines the significance of tumor-infiltrating lymphocytes (TILs) in various breast cancer types and emphasizes the need for standardized TIL evaluation methods to improve patient outcomes.

The FDA issued a complete response letter for sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control.

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

Patients with the BRAF V600E mutation and metastatic colorectal cancer (CRC) can be treated with a combination of encorafenib with cetuximab and mFOLFOX6.

The FDA granted approval to Steqeyma (ustekinumab-stba) for inflammatory conditions, making it the seventh biosimilar to reference Stelara after a year of multiple ustekinumab biosimilar approvals.

Septal circumferential strain (Ecc) was significantly decreased in LGE-negative boys with Duchenne muscular dystrophy (DMD) and correlated to ventricle changes.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

GLP-1 drugs are remarkably effective at addressing obesity, cardiovascular, and metabolic conditions, but investigators continue to search for solutions that address the root cause of these disorders.

Our top content from the 100th annual American Heart Association (AHA) Scientific Sessions included exclusive expert insights and highlighted promising treatments.

Our top content for the year highlight many challenges the field of non–small cell lung cancer (NSCLC) encountered, with data showing both setbacks in clinical trial results and advancements in screening recommendations for at-risk patients.

Key findings from 2024 focused on conditions like vaccine-induced immune thrombotic thrombocytopenia, immune thrombocytopenia, and hemophilia, stressing the importance of early detection and innovative therapies.

Here are 5 key points on electronic cigarette use that cover industry marketing methods, harmful substances, associated health risks, regulations, and its links to mental health as well as the COVID-19 pandemic.

The top 5 podcasts for 2024 cover Medicare Advantage prior authorization, health equity, global immunization challenges, trauma-informed care, and health literacy.

Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.

Researchers study long-term safety of lentiviral gene therapy in primates, finding no evidence of somatic mutations or malignancy.

A national survey of Canadian hematologists reveals gaps and variability in supportive care strategies for older adults with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), emphasizing the need for evidence-based guidelines.

Finding similar frequencies of positive acetylcholine receptor antibodies in patients with ocular and generalized myasthenia gravis (MG), a Danish research team posits that ocular disease is most likely a more moderate form of generalized MG—not a fully separate condition.

The FDA has approved ensartinib in adult patients with anaplastic lymphoma kinase (ALK)–positive locally advanced or metastatic non–small cell lung cancer (NSCLC) naive to ALK treatment.

Dan Bloomfield, MD, chief medical officer, Anthos, walks through promising findings demonstrating the efficacy of abelacimab, a factor XI (FXI) inhibitor, to reduce bleeding risk in atrial fibrillation treatment.

Cognitive and behavioral techniques can improve physical function and overall well-being in patients with long COVID.

Among the most-read coverage for the annual meeting were presentations on the potential and costs of cell and gene therapies, the latest trends in the industry, and pharmacogenomic testing in mental health.

The CONNECT2-EDO51 phase 2 trial looks at PGN-EDO51, an investigational therapy for Duchenne muscular dystrophy (DMD), and is still ongoing in the United Kingdom.

Stigma surrounding HIV can lead to barriers to health care, including refusal to get care, that could help individuals who are living with the condition.

The rate of frailty among patients with multiple sclerosis (MS) ranges from 17% to 66% among ambulatory patients, and frailty among MS patients is linked to a host of complications.

In 2024, the most-read articles published in our flagship peer-reviewed journal, The American Journal of Managed Care® (AJMC®), touched on disease burden, policy consequences, and more.

Based on their findings, the researchers suggest the integration of automated measures to identify interventricular septal (IVS) flattening in these patients.

The top 5 most-viewed content from CHEST 2024 included expert interviews and coverage on multiple areas of chest medicine.

From imaging innovations to new treatment approvals, 2024 brought advancements in Duchenne muscular dystrophy care and research.